These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 21628305)

  • 21. Cost-utility analysis of caspofungin and fluconazole for primary treatment of invasive candidiasis and candidemia in Ethiopia.
    Gebretekle GB; Fentie AM; Gebremariam GT; Ali EE; Erku DA; Alemayehu T; Abebe W; Sander B
    BMC Health Serv Res; 2022 Oct; 22(1):1302. PubMed ID: 36309674
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Economic impact of caspofungin as compared with liposomal amphotericin B for empirical therapy in febrile neutropenia in Australia.
    Al-Badriyeh D; Liew D; Stewart K; Kong DC
    J Antimicrob Chemother; 2009 Jun; 63(6):1276-85. PubMed ID: 19346292
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anidulafungin: a new echinocandin with a novel profile.
    Vazquez JA
    Clin Ther; 2005 Jun; 27(6):657-73. PubMed ID: 16117974
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment and prophylaxis of invasive candidiasis with anidulafungin, caspofungin and micafungin and its impact on use and costs: review of the literature.
    Wilke M
    Eur J Med Res; 2011 Apr; 16(4):180-6. PubMed ID: 21486732
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Posaconazole vs fluconazole/itraconazole in the prophylaxis of invasive fungal infections in immunocompromised patients: a cost-effectiveness analysis in Greece.
    Athanasakis K; Petrakis I; Kyriopoulos J
    J Med Econ; 2013; 16(5):678-84. PubMed ID: 23448409
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Economic analysis of micafungin versus liposomal amphotericin B for treatment of candidaemia and invasive candidiasis in Germany.
    Cornely OA; Sidhu M; Odeyemi I; van Engen AK; van der Waal JM; Schoeman O
    Curr Med Res Opin; 2008 Jun; 24(6):1743-53. PubMed ID: 18477422
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anidulafungin in the treatment of patients with invasive candidiasis.
    Kett DH; Cubillos GF
    Int J Antimicrob Agents; 2008 Nov; 32 Suppl 2():S99-S102. PubMed ID: 19013348
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness of primary antifungal prophylaxis with posaconazole versus itraconazole in allogeneic hematopoietic stem cell transplantation.
    Sánchez-Ortega I; Patiño B; Muñoz C; Arnan M; Peralta T; Clopés A; de Sevilla AF; Duarte RF
    J Med Econ; 2013; 16(6):736-43. PubMed ID: 23541251
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacoeconomic evaluation of fluconazole, posaconazole and voriconazole for antifungal prophylaxis in patients with acute myeloid leukaemia undergoing first consolidation chemotherapy.
    Heng SC; Slavin MA; Al-Badriyeh D; Kirsa S; Seymour JF; Grigg A; Thursky K; Bajel A; Nation RL; Kong DC
    J Antimicrob Chemother; 2013 Jul; 68(7):1669-78. PubMed ID: 23485723
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antifungal treatment for invasive Candida infections: a mixed treatment comparison meta-analysis.
    Mills EJ; Perri D; Cooper C; Nachega JB; Wu P; Tleyjeh I; Phillips P
    Ann Clin Microbiol Antimicrob; 2009 Jun; 8():23. PubMed ID: 19558681
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Micafungin versus anidulafungin in critically ill patients with invasive candidiasis: a retrospective study.
    van der Geest PJ; Hunfeld NG; Ladage SE; Groeneveld AB
    BMC Infect Dis; 2016 Sep; 16():490. PubMed ID: 27634140
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of invasive candidiasis: between guidelines and daily clinical practice.
    Tagliaferri E; Menichetti F
    Expert Rev Anti Infect Ther; 2015 Jun; 13(6):685-9. PubMed ID: 25818660
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness of micafungin as an alternative to fluconazole empiric treatment of suspected ICU-acquired candidemia among patients with sepsis: a model simulation.
    Zilberberg MD; Kothari S; Shorr AF
    Crit Care; 2009; 13(3):R94. PubMed ID: 19545361
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Empirical anti-Candida therapy among selected patients in the intensive care unit: a cost-effectiveness analysis.
    Golan Y; Wolf MP; Pauker SG; Wong JB; Hadley S
    Ann Intern Med; 2005 Dec; 143(12):857-69. PubMed ID: 16365467
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Economic evaluation of posaconazole vs fluconazole in the prevention of invasive fungal infections in patients with GVHD following haematopoietic SCT.
    de la Cámara R; Jarque I; Sanz MA; Grau S; Casado MA; Sabater FJ; Carreras E
    Bone Marrow Transplant; 2010 May; 45(5):925-32. PubMed ID: 19802030
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness evaluation of voriconazole versus liposomal amphotericin B as empirical therapy for febrile neutropenia in Australia.
    Al-Badriyeh D; Liew D; Stewart K; Kong DC
    J Antimicrob Chemother; 2009 Jan; 63(1):197-208. PubMed ID: 19001450
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of invasive candidiasis with echinocandins.
    Glöckner A; Steinbach A; Vehreschild JJ; Cornely OA
    Mycoses; 2009 Nov; 52(6):476-86. PubMed ID: 19076282
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Therapy of candidemia and invasive candidiasis according to guidelines].
    Glöckner A
    Mycoses; 2010 May; 53 Suppl 1():30-5. PubMed ID: 20433654
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anidulafungin compared with fluconazole for treatment of candidemia and other forms of invasive candidiasis caused by Candida albicans: a multivariate analysis of factors associated with improved outcome.
    Reboli AC; Shorr AF; Rotstein C; Pappas PG; Kett DH; Schlamm HT; Reisman AL; Biswas P; Walsh TJ
    BMC Infect Dis; 2011 Sep; 11():261. PubMed ID: 21961941
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adapting a global cost-effectiveness model to local country requirements: posaconazole case study.
    Papadopoulos G; Hunt S; Prasad M
    J Med Econ; 2013; 16(3):374-80. PubMed ID: 23256900
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.